Neuroleptic Malignant Syndrome after Addition of Paroxetine to Olanzapine [6]

Journal of Clinical Psychopharmacology

Volumn 23, Issue 6, 2003, Pages 671-672

  Kontaxakis, Vassilis P ^a   Havaki Kontaxaki, Beata J ^a   Pappa, Dimitra A ^a   Katritsis, Dimosthenis E ^a   Christodoulou, George N ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BIPERIDEN; HALOPERIDOL; LEVOMEPROMAZINE; LORAZEPAM; MIRTAZAPINE; OLANZAPINE; PAROXETINE;

ADULT; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DETERIORATION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG RESPONSE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; LETTER; MEDICAL EXAMINATION; MONOTHERAPY; NEUROLEPTIC MALIGNANT SYNDROME; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

BENZODIAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; PAROXETINE; SEROTONIN UPTAKE INHIBITORS;

EID: 0345283359     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000096245.29231.a8     Document Type: Letter

References (21)

1. Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, et al. Olanzapine associated neuroleptic malignant syndrome. Progr Neuropsychopharm & Biol Psychiatry. 2002;26:896-902.
2. Halman M, Goldbloom DS. Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry. 1990;28:518-521.
3. Heinemann F, Assion HJ, Hermes G, et al. Paroxetine - induced neuroleptic malignant syndrome. Nervenarzt. 1997;68:664-666.
4. Nimmagadda SR, Ryan DH, Atkin SL. Neuroleptic malignant syndrome after venlafaxine. Lancet. 2000;354:289-290.
5. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatrry. 1985;142:1137-1145.
6. Shelton RC, Tollefson GD, Tohem M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158:131-134.
7. Pies RW. Must we consider SSRI's neuroleptics? J Clin Psychopharmacol. 1997;17:443-445.
8. Lane R, Baldwin D. Selective serotonin reuptake inhibitors induced serotonin syndrome: review. J Clin Psychopharmacol. 1997;17:208-221.
9. Verhoeven MAW, Tuinier S. The serotonin syndrome: Four case reports and a concise review of the literature. Eur J Psychiat. 1998; 12:12-18.
10. Fink M. Toxic serotonin syndrome or neuroleptic malignant syndrome? Pharmacopsychiatry. 1996;29:159-161.
11. Ames D, Wirshing WC. Ecstasy, the serotonin syndrome and neuroleptic malignant syndrome - a possible link [letter]. JAMA. 1993; 269:869-870.
12. Sternback H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-713.
13. Fink M, Taylor MA. The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci. 2001;251(Suppl 1):8-13.
14. Kontaxakis VP, Havaki-Kontaxaki BJ, Stamouli SS, et al. Toxic interaction between risperidone and clozapine: a case report. Progr Neuropsychopharmacol Biol Psychiatry. 2002;26:407-409.
15. Berardi D, Amore M, Keck PE Jr, et al. Clinical and pharmacological risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry. 1998;44:748-754.
16. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab. 2002;3(1):13-37.
17. Rao ML, Hiemke C, Grasmader K, et al. Olanzapine 1: Pharmacology, pharmacokinetics and therapeutic drug monitoring. Fortschr Neurol Psychiatr. 2001;69(11):510-517.
18. Choo V. Paroxetine and extrapyramidal reactions [Ietter]. Lancet. 1993;158:6931-6932.
19. Caley CF. Extrapyramidal reactions and the selective serotonin reuptake inhibitors. Ann Pharmacother. 1997;31:1481-1489.
20. Liston HL, Markowitz JS, DeVane CL. Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol. 2001:21(5):500-515.
21. Kaufman KR, Gemer R. Lamotrigine toxicity secondary to sertraline. Seizure. 1998;7(2):163-165.